IBRANCE (palbociclib)
ANTINEOPLASTIC- CYCLIN-DEPENDENT KINASE (CDK) 4/6 INHIBITORS·HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER·+2
Parke-Davis Pfizer
Indication
Hormone receptor (HR)-positive, HER2-negative advanced breast cancer
Hormone receptor (HR)-positive, HER2-negative advanced breast cancer refers to a malignancy originating in mammary tissue that has progressed to locally advanced, unresectable disease or disseminated to distant metastatic sites. Read more about Hormone receptor (HR)-positive, HER2-negative advanced breast cancer
8 drugs 7 manufacturers
Drugs that treat it
Common Hormone receptor (HR)-positive, HER2-negative advanced breast cancer therapies.
KISQALI (ribociclib succinate)
ANTINEOPLASTIC- CYCLIN-DEPENDENT KINASE (CDK) 4/6 INHIBITORS·HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER·+1
Novartis Pharmaceuticals
KISQALI FEMARA CO-PACK (ribociclib succinate/letrozole)
HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER·+1
Novartis Pharmaceuticals
VERZENIO (abemaciclib)
ANTINEOPLASTIC- CYCLIN-DEPENDENT KINASE (CDK) 4/6 INHIBITORS·HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER·+2
Eli Lilly and Company
TRODELVY (sacituzumab govitecan-hziy)
PD-L1 EXPRESSING TRIPLE-NEGATIVE BREAST CANCER·+2
IMMUNOMEDICS
TRODELVY (sacituzumab govitecan-hziy)
ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS·PD-L1 EXPRESSING TRIPLE-NEGATIVE BREAST CANCER·+2
GILEAD SCIENCES
DATROWAY (datopotamab deruxtecan-dlnk)
EPIDERMAL GROWTH FACTOR RECEPTOR POSITIVE NON-SMALL CELL LUNG CANCER·+3
DAIICHI SANKYO,
KISQALI (ribociclib succinate)
ANTINEOPLASTIC- CYCLIN-DEPENDENT KINASE (CDK) 4/6 INHIBITORS·HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER·+1
Novartis Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with Hormone receptor (HR)-positive, HER2-negative advanced breast cancer preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHormone receptor (HR)-positive, HER2-negative advanced breast cancer refers to a malignancy originating in mammary tissue that has progressed to locally advanced, unresectable disease or disseminated to distant metastatic sites.
Pathophysiologically, tumor cells demonstrate significant expression of estrogen and/or progesterone receptors—which serve as principal intracellular drivers of oncogenic signaling and proliferation—while lacking human epidermal growth factor receptor 2 gene amplification or protein overexpression.
This clinical presentation predominantly affects adult women, though it may also occur in men, and represents the most prevalent biological subtype of advanced mammary carcinoma.
Clinically, it reflects an incurable yet treatable chronic oncologic state characterized by systemic disease burden and variable sensitivity or acquired resistance to endocrine-based therapies.
- cancer.gov
Hormone receptor (HR)-positive, HER2-negative advanced breast cancer refers to a malignancy originating in mammary tissue that has progressed to locally advanced, unresectable disease or disseminated to distant metastatic sites Pathophysiologically, tumor cells demonstrate significant expression of estrogen and/or progesterone receptors—which serve as principal intracellular drivers of oncogenic signaling and proliferation—while lacking human epidermal growth factor receptor 2 gene amplification...
- nih.gov
Hormone receptor (HR)-positive, HER2-negative advanced breast cancer refers to a malignancy originating in mammary tissue that has progressed to locally advanced, unresectable disease or disseminated to distant metastatic sites This clinical presentation predominantly affects adult women, though it may also occur in men, and represents the most prevalent biological subtype of advanced mammary carcinoma Clinically, it reflects an incurable yet treatable chronic oncologic state characterized by sy...
- cancer.gov
Hormone receptor (HR)-positive, HER2-negative advanced breast cancer refers to a malignancy originating in mammary tissue that has progressed to locally advanced, unresectable disease or disseminated to distant metastatic sites
- cancer.gov
Pathophysiologically, tumor cells demonstrate significant expression of estrogen and/or progesterone receptors—which serve as principal intracellular drivers of oncogenic signaling and proliferation—while lacking human epidermal growth factor receptor 2 gene amplification or protein overexpression
- honcology.com
Pathophysiologically, tumor cells demonstrate significant expression of estrogen and/or progesterone receptors—which serve as principal intracellular drivers of oncogenic signaling and proliferation—while lacking human epidermal growth factor receptor 2 gene amplification or protein overexpression
- clevelandclinic.org
This clinical presentation predominantly affects adult women, though it may also occur in men, and represents the most prevalent biological subtype of advanced mammary carcinoma
- breastcancer.org
This clinical presentation predominantly affects adult women, though it may also occur in men, and represents the most prevalent biological subtype of advanced mammary carcinoma
- healthbooktimes.org
Clinically, it reflects an incurable yet treatable chronic oncologic state characterized by systemic disease burden and variable sensitivity or acquired resistance to endocrine-based therapies
Personalize your experience
Follow Hormone receptor (HR)-positive, HER2-negative advanced breast cancer and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.